Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q2 FY20 results · Jul–Sep 2019
Panacea Biotec reported revenue from operations of ₹125.18 crore and net loss of ₹75.00 crore for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 125.18 | — | — | 125.78 | −0.5% |
| Other income | 3.45 | — | — | 5.03 | −31.4% |
| Total income | 128.63 | — | — | 130.81 | −1.7% |
| Profit before share of associates & JVs and tax | (70.50) | — | — | (23.75) | Loss widened |
| Share of profit/(loss) of associates & JVs | 0.03 | — | 0.07 | ||
| Net profit for the period | (75.00) | — | — | (28.27) | Loss widened |
| EPS, basic (₹) | (12.25) | — | — | (4.62) | Loss widened |
| Net margin (%) | -59.9 | — | -22.5 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 20.98 | 118.58 | −82.3% | 24.82 | −15.5% |
| Other income | 0.77 | 3.30 | −76.7% | 1.14 | −32.5% |
| Total income | 21.75 | 121.88 | −82.2% | 25.96 | −16.2% |
| Profit before tax | (54.54) | (94.83) | Loss narrowed | (18.81) | Loss widened |
| Net profit for the period | (71.64) | (97.49) | Loss narrowed | (29.21) | Loss widened |
| EPS, basic (₹) | (11.70) | (15.92) | Loss narrowed | (4.77) | Loss widened |
| Net margin (%) | -341.5 | -82.2 | -117.7 |
Consolidated
- Filed with BSE
- 19 Nov 2019, 15:48 IST
- Board meeting
- 14 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 Nov 2019, 15:48 IST
- Board meeting
- 14 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE